Atlas Trials

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Clinical trial NCT04003168 · UNKNOWN

Trial details

NCT number
NCT04003168
Sponsor
Hrain Biotechnology Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2019-07-01
Primary completion
2022-07-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.